- Adults (18-64 years)
- General population
- Hospital
- Intensive care unit
- SARS-CoV-2
- Influenza virus
- Influenza A(H5N1) virus
- Acute COVID-19
- Avian Influenza
- Influenza
- Pharmacological intervention
- Immunomodulator
- Baricitinib
- Statins
- Simvastatin
Population: General population
Individuals who do not belong to a defined subgroup with specific characteristics, representing the broader population
- Adults (18-64 years)
- General population
- Hospital
- SARS-CoV-2
- Influenza virus
- Influenza A(H5N1) virus
- Acute COVID-19
- Avian Influenza
- Influenza
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- Community
- Non-hospital health centre
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Primary care
- Monkeypox virus
- Mpox
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Hospital
- Outpatient clinic
- Monkeypox virus
- Mpox
- Pharmacological intervention
- Antivirals
- Cidofovir
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Monoclonal antibodies
- Immunomodulator
- Antineoplastic agent
- Imatinib
- Infliximab
- General population
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Healthcare workers
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19